LOCALITY 27 WAR 2006 ISBNOR

## Application No. Unknown INFORMATION DISCLOSURE Filing Date Herewith First Named Inventor Kuhara, et al STATEMENT BY APPLICANT Art Unit Unknown (Multiple sheets used when necessary) Examiner Unknown TOYA108.014APC SHEET 1 OF 1 Attorney Docket No.

	U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear		
	1						

•	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T¹	

	NON PATENT LITERATURE DOCUMENTS	
Cite No.	The managine investigation coincides and the contract of the c	
	Kasaian, et al. "Cyclosporin a Inhibition of Interleukin 2 Gene Expression, But Not Natural Killer Cell Proliferation, After Interferon Induction In Vivo," <i>Journal of Experimental Medicine</i> , Vol. 171, pp. 745-762, 1990.	
	Kuhara, et al. "Oral Administration of Lactoferrin Raises NK Cell Activity in Mice," Milk Science, Vol. 53, No. 4, pp. 262-264, 2004.	
	Riccardi, et al. "Generation of Mouse Natural Killer (NK) Cell Activity: Effect of Interleukin-2 (IL-2) and Interferon (IFN) on the <i>In Vivo</i> Development of Natural Killer Cells From Bone Marrow (BM) Progenitor Cells," <i>International Journal of Cancer</i> , Vol. 38, pp. 553-562, 1986.	
	Tsuda, et al. "Inhibition of Carcinogenesis by Bovine Lactoferrin and Analysis of Mechanisms," FFI Journal, No. 200, pp. 27-35, 2002 (in Japanese).	Summar
	Tsuda, et al. "Cancer Prevention by Bovine Lactoferrin and Underlying Mechanisms—A Review of Experimental and Clinical Studies," <i>Biochem. Cell Biol.</i> , Vol. 80, pp. 131-136, 2002	
	Wang, et al. "Activation of Intestinal Mucosal Immunity in Tumor-Bearing Mice by Lactoferrin" Japanese Journal of Cancer Research, Vol. 91, pp. 1022-1027, October 2000.	
	International Search Report dated September 28, 2005 (in Japanese).	
		Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Kasaian, et al. "Cyclosporin a Inhibition of Interleukin 2 Gene Expression, But Not Natural Killer Cell Proliferation, After Interferon Induction In Vivo," Journal of Experimental Medicine, Vol. 171, pp. 745-762, 1990.  Kuhara, et al. "Oral Administration of Lactoferrin Raises NK Cell Activity in Mice," Milk Science, Vol. 53, No. 4, pp. 262-264, 2004.  Riccardi, et al. "Generation of Mouse Natural Killer (NK) Cell Activity: Effect of Interleukin-2 (IL-2) and Interferon (IFN) on the In Vivo Development of Natural Killer Cells From Bone Marrow (BM) Progenitor Cells," International Journal of Cancer, Vol. 38, pp. 553-562, 1985.  Tsuda, et al. "Inhibition of Carcinogenesis by Bovine Lactoferrin and Analysis of Mechanisms," FFI Journal, No. 200, pp. 27-35, 2002 (in Japanese).  Tsuda, et al. "Cancer Prevention by Bovine Lactoferrin and Underlying Mechanisms—A Review of Experimental and Clinical Studies," Biochem. Cell Biol., Vol. 80, pp. 131-136, 2002  Wang, et al. "Activation of Intestinal Mucosal Immunity in Tumor-Bearing Mice by Lactoferrin" Japanese Journal of Cancer Research, Vol. 91, pp. 1022-1027, October 2000.

2472561 032306

Examiner Signature Oartse	Date Considered	7.26.07
*Examiner: Initial if reference considered, whether or not citation is in c in conformance and not considered. Include copy of this form with next	conformance with MPEP 609 communication to applicant.	Draw line through citation if not

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

## 10/573,564 Application No. INFORMATION DISCLOSURE Filing Date March 27, 2006 First Named Inventor Kuhara, et al. STATEMENT BY APPLICANT Art Unit 1647 Landsman, Robert S. (Multiple sheets used when necessary) Examiner SHEET 1 OF 1 Attorney Docket No. TOYA108.014APC

U.S. PATENT DOCUMENTS							
Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			
			<u> </u>				
		Number - Kind Code (if known)	Cite Document Number Number - Kind Code (if known)  NMADD-YYYY	Cite Document Number Number - Kind Code (if known)  Name of Patentee or Applicant			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>		
,								
		<u> </u>						

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/o country where published.							
AL	Sivori, et al. "CpG and Double-Stranded RNA Trigger Human NK Cells by Toll-Like Receptors: Induction of Cytokine Release and Cytotoxicity Against Tumors and Dendritic Cells," <i>PNAS</i> , Vol. 101, No. 26, 10116-1012 6, 2004.		<u> </u>				
<u></u>							
	l	·					

3890816 061507

Examiner Signature

Partse

Date Considered

7.26.07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08 Equivale	nl
--------------------	----

STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

10/573,564
March 27, 2006
Kuhara, et al.
Unknown
Unknown
TOYA108.014APC

			U.S. PATENT	OCUMENTS	
Examiner Initials	Cite No.	Document Number  Number - Kind Code (if known)  Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	<del>  </del>				
	1 1				
		•	1		
	-		<del> </del>		
	1 1		1		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	τ¹		
BL		JP 2001-503430	03/13/01	Wisconsin Alumni Research Foundation		PCT 1 <sup>51</sup> Pg		
		JP 2002-515893	05/28/02	Pharming B.V.		PCT 1 <sup>st</sup> Pg		
		JP 2001-149069	06/05/01	Inst of Physical & Chemical Res		Abstract		
		WO 98/19675	05/14/98	Wisconsin Alumni Research Foundation	·	_		
1		WO 98/33509	08/06/98	Pharming BIV.				
			<u></u>	·				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials  Cite No.  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
BL		Porgador, et al. "Natural Killer Cell Lines Kill Autologous β <sub>2</sub> -Microglobulin-Deficient Melanoma Cells: Implications for Cancer Immunotherapy," <i>Proc. Natl. Acad. Sci.</i> , USA, Vol. 94, pp. 13140-13145, 1997.	
Ì		Molecular Medicine, Vol. 39, pp. 238-246, 2002. Hemmi and Akira	Partial
		Molecular Medicine, Vol. 40, pp. 186-193, 2003. A Kira S	Partial
<del></del>	1		

2619649 052206

Examiner Signature Quite

Date Considered

7.26.07

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.